In particular, we have demonstrated the potential role of this specific splice variant of the PDE4D gene for prognosis of aggressive prostate cancer in the molecular sub-type of TMPRSS2-ERG-positive prostate tumours as well as its role as a putative target gene for therapy of primary vs late-stage, hormone-refractory disease. This evidence concerns the gene PDE4D and prostate cancer.